Intangible Assets, Net (Tables)

6 Months Ended

Jun. 30, 2012

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule Of Intangible Assets, Net

	June 30, 2012		December 31, 2011
In-process research and development acquired in the Anchen Acquisition, net of     accumulated amortization of $0 and $0	$	124,700	126,700
Developed products acquired in the Anchen Acquisition, net of accumulated amortization of $13,036 and $1,650	72,164		83,550
QOL Medical, LLC Asset Purchase Agreement, net of accumulated amortization of $14,820 and $12,540	39,901		42,181
Teva Pharmaceuticals, Inc. Asset Purchase Agreement, net of accumulated amortization of $2,664 and $1,255	15,336		16,745
Glenmark Generics Limited and Glenmark Generics, Inc. USA Licensing Agreement, net     of accumulated amortization of $0 and $0	15,000		15,000
Synthon Pharmaceuticals, Inc. Asset Purchase Agreement, net of accumulated     amortization of $0 and $0	9,600		9,600
Covenant not-to-compete acquired in the Anchen Acquisition, net of accumulated amortization of $1,842 and $358	7,059		8,542
Teva Pharmaceuticals, Inc. License and Distribution Agreement, net of accumulated amortization of $4,000 and $0	2,000		6,000
In-process research and development acquired in the Edict Acquisition, net of accumulated amortization of $0	1,100		—
Genpharm, Inc. Distribution Agreement, net of accumulated amortization of $10,109         and $9,748	724		1,085
Covenant not-to-compete acquired in the Edict Acquisition, net of accumulated     amortization of $94	656		—
SVC Pharma LP License and Distribution Agreement, net of accumulated amortization of $3,278 and $3,034	406		650
Other intangible assets, net of accumulated amortization of $7,231 and $7,209	391		414
Trademark licensed from Bristol-Myers Squibb Company, net of accumulated amortization of $10,000 and $9,148	—		852
MDRNA, Inc. Asset Purchase Agreement, net of accumulated amortization of $2,100       and $1,750	—		350
	$	289,037	$	311,669

Schedule Of Estimated Amortization Expense

	Estimated Amortization Expense
2012	$	15,820
2013	33,711
2014	47,304
2015	44,602
2016	39,691
2017 and thereafter	107,909
	$	289,037